A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors

Phosphatidylinositol 3-kinase (PI3K) pathway activation is associated with resistance to paclitaxel in solid tumors. We assessed the safety and activity of alpelisib, an oral, selective PI3K p110α inhibitor, plus paclitaxel in patients with advanced solid tumors. This Phase Ib, multicenter, open-lab...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodon, Jordi, Curigliano, Giuseppe, Delord, Jean-Pierre, Harb, Wael, Azaro, Analia, Han, Yu, Wilke, Celine, Donnet, Valerie, Sellami, Dalila, Beck, Thaddeus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114962/
https://www.ncbi.nlm.nih.gov/pubmed/30167089
http://dx.doi.org/10.18632/oncotarget.25854

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114962/
https://www.ncbi.nlm.nih.gov/pubmed/30167089
http://dx.doi.org/10.18632/oncotarget.25854

Ejemplares similares